Genomics, public health and developing countries: the case of the Mexican National Institute of Genomic Medicine (INMEGEN)
- 1 October 2008
- journal article
- Published by Springer Science and Business Media LLC in Nature Reviews Genetics
- Vol. 9 (S1), S5-S9
- https://doi.org/10.1038/nrg2442
Abstract
In 2004, the government of Mexico established the National Institute of Genomic Medicine (INMEGEN), to carry out disease-related genomic studies that will address national health problems and stimulate scientific and technological development by generating new commercial products and services in genomic medicine. Towards this end, INMEGEN is carrying out a large-scale genotyping project to map genomic variation within its own population. The initiative is expected to generate a key resource for local researchers to understand disease susceptibility and variation in drug responses, which will contribute to Mexico's goal of developing public health genomics - a field in which Mexico is proving to be a leader amongst emerging economies.Keywords
This publication has 19 references indexed in Scilit:
- Human genomic variation initiatives in emerging economies and developing countriesNature Reviews Genetics, 2008
- Genomic medicine and developing countries: creating a room of their ownNature Reviews Genetics, 2008
- Global variation in copy number in the human genomeNature, 2006
- Scientific DiasporasScience, 2006
- Reinventing global health: the role of science, technology, and innovationThe Lancet, 2005
- When two tribes go to warNature, 2004
- Developing a Platform for Genomic Medicine in MexicoScience, 2003
- Tribe blasts 'exploitation' of blood samplesNature, 2002
- Indi-GENE-ous ConflictsEnvironmental Health Perspectives, 2001
- Report Casts Doubt on Korean ExperimentScience, 1999